Biotech之间的并购。6500万美元估值。
$Surface Oncology(SURF)$ $Coherus生物科技(CHRS)$(surf 开盘33%,收盘上涨7%,chrs下跌23%)
SURF & CHRS announced that they have entered into a merger agreement providing that Coherus will acquire Surf...查看全文
Surface Oncology(SURF)2023-06-16 20:15
$Surface Oncology(SURF)$ 425 Prospectuses and communications, business combinations Accession Number: 0001193125-23-168499 Size: 1 MB 网页链接查看全文
Surface Oncology(SURF)2023-05-17 21:10
$Surface Oncology(SURF)$ CT ORDER Confidential treatment order Accession Number: 9999999997-23-002905 Act: 33 Size: 122 KB 网页链接查看全文
Surface Oncology(SURF)2023-05-04 19:12
$Surface Oncology(SURF)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001718108-23-000013 Act: 34 Size: 5 MB 网页链接查看全文
逍遥谷-百奥生2023-04-27 14:03
$Surface Oncology(SURF)$ 股价一年内已经跌了70%左右,2,3年内跌了近90%,补仓了。希望能是第二个emis.
$工艺酿酒联盟(HOOK)$ 希望已经触底,从反弹到反转。查看全文
逍遥谷-百奥生2022-11-05 02:28
$工艺酿酒联盟(HOOK)$
2月16日,在去年秋天退出与 Hookipa Pharma 的 HIV 治疗合作后,Gilead $吉利德科学(GILD)$ 又与该公司开展了合作。两家公司修改了他们的许可协议,为Hookipa提供 1500 万美元的预付款和高达 2.37 亿美元的 里程金。
Hookipa 在 2021 年 11 月披露,吉利德上个月根...查看全文
牛唐2018-07-31 16:44
$Surface Oncology(SURF)$ FDA授予治疗多发性骨髓瘤的SRF231孤儿药资格,它是一款靶向CD47的单抗药物,是继$Forty Seven(FTSV)$ 的Hu5F9-G4、$Trillium Therapeutics Inc. (TRIL)$ 的TTI-621之后的第三个靶向CD47的孤儿药查看全文
智通财经APP获悉,据媒体消息,专攻免疫疗法的Surface Oncology(SURF.US)公司收到了葛兰素史克(GSK.US)的收购意向。 报道称,除葛兰素史克之外,Surface Oncology还在寻找其它任何可能的收购者。 此前,百时美施贵宝(BMY.US)在同意收... 网页链接
$Surface Oncology(SURF)$ 15-12G Securities registration termination [Section 12(g)] Accession Number: 0001193125-23-236303 Act: 34 Size: 12 KB 网页链接
$Surface Oncology(SURF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002629 Act: 33 Size: 1 KB 网页链接
$Surface Oncology(SURF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002628 Act: 33 Size: 1 KB 网页链接
$Surface Oncology(SURF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-23-231522 Act: 33 Size: 21 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231530 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231534 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231535 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231539 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231542 Act: 33 Size: 23 KB 网页链接
$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231544 Act: 33 Size: 23 KB 网页链接